A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations

被引：5
|
作者：
Hong, M. H. [1 ]
Spira, A. I. [2 ]
Lee, K. H. [3 ]
Cho, E. K. [4 ]
Han, J-Y. [5 ]
Shim, B. Y. [6 ]
Lee, J-S. [7 ]
Kao, S. C-H. [8 ]
Kim, S-W. [9 ]
Khattak, A. [10 ]
Patel, M. [11 ]
Xu, R. [11 ]
Wang, J. [11 ]
Ariazi, E. [12 ]
Daemen, A. [12 ]
Maneval, E. Chow [11 ]
Multani, P. S. [11 ]
Patel, R. [11 ]
Ahn, M-J. [13 ]
机构：
[1] Yonsei Univ, Severance Hosp, Dept Internal Med, Coll Med, Seoul, South Korea
[2] Virginia Canc Specialist & Next Oncol, Res Inst, Fairfax, VA USA
[3] Chungbuk Natl Univ Hosp, Dept Internal Med, Cheongju, South Korea
[4] Gachon Univ, Dept Internal Med, Gil Hosp, Incheon, South Korea
[5] Natl Canc Ctr, Ctr Lung Canc, Grad Sch Canc Sci & Policy, Goyang, South Korea
[6] Catholic Univ Korea, Dept Med Oncol, St Vincents Hosp, Suwon, South Korea
[7] Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Seongnam, Gyeonggi Do, South Korea
[8] Chris OBrien Lifehouse, Med Oncol Dept, Camperdown, NSW, Australia
[9] Univ Ulsan, Dept Oncol, Asan Med Ctr, Seoul, South Korea
[10] Hollywood Med Ctr, One Clin Res, Med Oncol, Nedlands, WA, Australia
[11] ORIC Pharmaceut Inc, Clin Dev, San Diego, CA USA
[12] ORIC Pharmaceut Inc, Translat Med, San Diego, CA USA
[13] Sungkyunkwan Univ, Dept Hematol Oncol, Samsung Med Ctr SMC, Sch Med, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2366
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1333P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase 2 study of poziotinib in patients with EGFR or HER2 exon 20 mutation-positive non-small cell lung cancer
    Yang, Zandong
    Tchekmedyian, Nishan
    Chu, David T.
    Reddy, Guru
    Bhat, Gajanan
    Socinski, Mark A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] A phase 1 study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours
    Cresti, N.
    Jodrell, D.
    Arkenau, T.
    Forster, M.
    Donaldson, K.
    Posner, J.
    Kawabata, I.
    Plummer, R.
    Spicer, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S160 - S161
  • [33] Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer
    Robichaux, Jacqulyne P.
    Elamin, Yasir Y.
    Tan, Zhi
    Carter, Brett W.
    Zhang, Shuxing
    Liu, Shengwu
    Li, Shuai
    Chen, Ting
    Poteete, Alissa
    Estrada-Bernal, Adriana
    Le, Anh T.
    Truini, Anna
    Nilsson, Monique B.
    Sun, Huiying
    Roarty, Emily
    Goldberg, Sarah B.
    Brahmer, Julie R.
    Altan, Mehmet
    Lu, Charles
    Papadimitrakopoulou, Vassiliki
    Politi, Katerina
    Doebele, Robert C.
    Wong, Kwok-Kin
    Heymach, John V.
    NATURE MEDICINE, 2018, 24 (05) : 638 - +
  • [34] Updated data from the phase 1 trial of DZD1516, a BBB-penetrant selective HER2 inhibitor, in patients with HER2 positive metastatic breast cancer
    McAndrew, Nicholas P.
    Hu, Xichun
    Zhang, Jian
    Wang, Xiaojia
    Yu, Wenlei
    Pan, Xiaomei
    CANCER RESEARCH, 2023, 83 (05)
  • [35] A phase Ⅰ study of Hemay022, an irreversible dual EGFR/HER2 tyrosine kinase inhibitor in Chinese patients with HER2-positive advanced breast cancer
    Pin Zhang
    Lin Wang
    Yueying Zhen
    Zhihong Wang
    Hesheng Zhang
    Richard Jones
    Binghe Xu
    Chinese Journal of Cancer Research, 2024, 36 (01) : 46 - 54
  • [36] ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations
    Socinski, M. A.
    Cornelissen, R.
    Garassino, M. C.
    Clarke, J.
    Tchekmedyian, N.
    Molina, J.
    Goldman, J. W.
    Bhat, G.
    Lebel, F.
    Le, X.
    ANNALS OF ONCOLOGY, 2020, 31 : S1188 - S1188
  • [37] Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors
    S. Tjulandin
    V. Moiseyenko
    V. Semiglazov
    G. Manikhas
    M. Learoyd
    A. Saunders
    M. Stuart
    U. Keilholz
    Investigational New Drugs, 2014, 32 : 145 - 153
  • [38] Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors
    Tjulandin, S.
    Moiseyenko, V.
    Semiglazov, V.
    Manikhas, G.
    Learoyd, M.
    Saunders, A.
    Stuart, M.
    Keilholz, U.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (01) : 145 - 153
  • [39] Beamion LUNG-1: Phase Ia/b Trial of HER2 Tyrosine Kinase Inhibitor Zongertinib (BI 1810631) in Patients with HER2 Aberration-Positive Solid Tumors
    Heymach, John
    Yamamoto, Noboru
    Opdam, Frans
    Barve, Minal
    Tu, Hai-Yan
    Wu, Yi-Long
    Schroeter, Lukas
    Sadrolhefazi, Behbood
    Serra, Josep
    Yoh, Kiyotaka
    Berz, David
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E1 - E1
  • [40] A PHASE 1 STUDY OF MM-111; A BISPECIFIC HER2/HER3 ANTIBODY FUSION PROTEIN, COMBINED WITH MULTIPLE TREATMENT REGIMENS IN PATIENTS WITH ADVANCED HER2 POSITIVE SOLID TUMORS
    Richards, D.
    Braiteh, F.
    Anthony, S.
    Edenfield, W.
    Hellerstedt, B.
    Raju, R.
    Conkling, P.
    McDonagh, C.
    Frye, S.
    Moyo, V.
    ANNALS OF ONCOLOGY, 2012, 23 : 170 - 170
12345